Antares Pharma’s Oral Testosterone Treatment Scores FDA Approval
Antares Pharma Inc (NASDAQ:ATRS) has nabbed another FDA approval, and the Company’s second involving testosterone. The Company announced FDA approval…
Lipocine Press Release Confirms Partner Antares Pharma Received FDA Approval For TLANDO
Commercial launch expected in 2Q 2022
SALT LAKE CITY, March 29, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products forCommercial launch expected in 2Q 2022
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Antares Pharma’s Return On Capital Employed Overview
According to Benzinga Pro, during Q4, Antares Pharma (NASDAQ:ATRS) earned $32.68 million, a 506.03% increase from the preceding quarter. Antares Pharma also posted a total of $48.73 million in sales, a 1.12% increase since Q3.
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell
• Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million.
Assertio Shares Gain After Buying Antares’ Rheumatoid Arthritis Treatment For $44M
Antares Pharma Inc (NASDAQ: ATRS) divested Otrexup (methotrexate) injection to treat rheumatoid arthritis to a subsidiary of Assertio Holdings Inc (NASDAQ: ASRT) for
HC Wainwright & Co. Maintains Buy on Antares Pharma, Lowers Price Target to $5
HC Wainwright & Co. analyst Oren Livnat maintains Antares Pharma (NASDAQ:ATRS) with a Buy and lowers the price target from $5.5 to $5.